Results 81 to 90 of about 6,337 (198)
Health Science Reports, Volume 8, Issue 11, November 2025.ABSTRACT Background and Aims SARS‐CoV‐2 continues to pose global challenges, and current vaccines face limitations (variant escape, waning immunity). This review evaluates immunostimulatory adjuvants and nano‐adjuvants to enhance immune responses and optimize SARS‐CoV‐2 vaccine performance.
Peyman Kheirandish Zarandi +5 more
wiley +1 more source
Effect of Paxlovid on Neurodevelopmental Disorder Diagnosis Outcomes in Offspring of Mothers Infected with SARS-Cov-2 during Pregnancy [PDF]
The onset of the 2020 COVID-19 pandemic brought concern over the effects that this virus would have on pregnancy and fetal outcomes, specifically neurodevelopmental outcomes.
Rogers, Simone
core +1 more source
Health Science Reports, Volume 8, Issue 11, November 2025.ABSTRACT Background and Aims The re‐emergence of COVID‐19 in India and South Asia, driven by the Omicron variant (NB. 1.8.1), poses an urgent challenge to global pandemic preparedness amid waning citizen awareness and reduced monitoring. This review aims to examine the variant′s characteristics, assess its public health impact, and evaluate the ...
Abir Hasan Pranto +3 more
wiley +1 more source
Studying the efficacy of Nirmatrelvir and Ritonavir (Paxlovid) for outpatient treatment of COVID-19 in the pediatric population using real-world data from the National COVID Cohort Collaborative (N3C) [PDF]
This study analyzes the efficacy of Nirmatrelvir and Ritonavir (NMV-r; Paxlovid) for outpatient treatment of COVID-19 in the pediatric population in the age group 12-18 years by using real-world data from N3C. The study uses propensity matching to create
Kumar, Manish
core +1 more source
Developing New Drugs for the COVID‐19 Emergency: Anatomy of the U.S. Response
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 11, Page 780-790, November 2025.ABSTRACT Context To meet the need for effective treatments during the COVID‐19 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments—a process that normally took 4–12 years.
Thomas J. Moore +2 more
wiley +1 more source
Acta Crystallographica Section D, Volume 81, Issue 11, Page 630-645, November 2025.Two crystallographic fragment screening campaigns against SARS‐CoV‐2 nonstructural protein 1 resulted in the identification of 21 new hits.Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continues to threaten global health. This underpins the need for novel therapeutics against this virus.
Frank Lennartz +9 more
wiley +1 more source
Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment [PDF]
Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19.
Brewitz, Lennart +1 more
core +2 more sources
MoleculesAmidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized ...
Reham F. Barghash +6 more
doaj +1 more source
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments [PDF]
Objective: Unusual clinical course Background: SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment.
Cingolani, Antonella +8 more
core +1 more source